7 completed, 2 terminated. 5 Phase 2, 3 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Not applicable | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Interferon Alfa-n3: new trials by email Literature Review of Interferon Alfa-n3 trials Research Report on Interferon Alfa-n3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis - Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 40 | 2004-10-01 | 2013-07-02 |
| Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer recombinant interferon alfa, oblimersen sodium, pharmacological study - Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2003-08-01 | 2013-08-26 |
| Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2001-10-01 | 2013-06-05 |
| Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma recombinant interferon alfa, thalidomide, laboratory biomarker analysis - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 35 | 2001-07-01 | 2013-01-25 |
| Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma melphalan, recombinant interferon alfa, aldesleukin - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 36 | 2000-02-01 | 2017-07-12 |
| A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3 Interferon alfa-n3, Interferon alfa-n1 - HIV Infections | Not applicable | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 560 | 2021-11-03 | |
| Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients Interferon alfa-n3 - HIV Infections | Not applicable | Completed | Interferon Sciences | 45 | 2005-06-24 | |
| Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects Interferon alfa-n3 - HIV Infections | Not applicable | Completed | Interferon Sciences | 60 | 2005-06-24 | |
| Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection Interferon alfa-n3 - HIV Infections | Phase 1 | Completed | Purdue Frederick | 2005-06-24 |
HIV Infections (4) · AIDS-Related Complex (2) · Acquired Immunodeficiency Syndrome (2) · Carcinoma, Renal Cell (2) · Lymphoma, Follicular (1) · Melanoma (1) · Multiple Myeloma (1)
National Cancer Institute (NCI) (4) · Interferon Sciences (2) · Fred Hutchinson Cancer Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Purdue Frederick (1)
United States (9)
Alston B (1) · Daniel George (1) · Greaves W (1) · John Sweetenham (1) · Kim Margolin (1) · Kumi J (1) · Leona Holmberg (1) · Standiford H (1) · William Carson (1)
N01CM17101 (1), U01CA099118 (1), U10CA031946 (1)